Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients-Reference-Cited by-同舟云学术

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Published:2016-11-12 Issue:1 Volume:92 Page:37-41
ISSN:0361-8609
Container-title:American Journal of Hematology
language:en
Short-container-title:Am. J. Hematol.

Author:

Polverelli Nicola¹,Breccia Massimo²,Benevolo Giulia³,Martino Bruno⁴,Tieghi Alessia⁵,Latagliata Roberto²,Sabattini Elena⁶,Riminucci Mara⁷,Godio Laura⁸,Catani Lucia¹,Nicolosi Maura³,Perricone Margherita¹,Sollazzo Daria¹,Colafigli Gioia²,Campana Anna³,Merli Francesco⁵,Vitolo Umberto³,Alimena Giuliana²,Martinelli Giovanni¹,Lewis Russell E.⁹,Vianelli Nicola¹,Cavo Michele¹,Palandri Francesca¹

Affiliation:

1. Department of Experimental, Diagnostic and Specialty Medicine (DIMES); Institute of Hematology and Clinical Oncology “L. and A. Seràgnoli”, Sant'Orsola-Malpighi University Hospital; Bologna Italy

2. Cellular Biotechnologies and Hematology; University Sapienza; Rome Italy

3. Hematology; Città della Salute e della Scienza Hospital; Turin Italy

4. Division of Hematology; Azienda Ospedaliera 'Bianchi Melacrino Morelli'; Reggio Calabria Italy

5. Division of Hematology; Azienda Ospedaliera Arcispedale Santa Maria Nuova; Reggio Emilia Italy

6. Haematopathology Unit, Department of Experimental, Diagnostic and Specialty Medicine; S. Orsola-Malpighi Hospital, University of Bologna; Bologna

7. Haematopathology Unit, Cellular Biotechnologies and Hematology; University Sapienza; Rome Italy

8. Anatomia Patologica Generale e Oncogenetica Molecolare; Città della Salute e della Scienza Hospital and University; Torino Italy

9. Division of Infectious Diseases, Department of Medical and Surgical Sciences; University of Bologna; Italy

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/ajh.24572/fullpdf

Reference38 articles.

1. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes;Vardiman;Blood,2009

2. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment;Cervantes;Blood,2009

3. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment);Passamonti;Blood,2010

4. Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): A histochemical and morphometric study on sequential trephine biopsies;Thiele;Leukemia Res,1999

5. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis;Elliott;Leukemia Res,2007

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Pharmacodynamics of Ruxolitinib: A Review;Clinical Pharmacokinetics;2023-03-31

2. Patient-specific comorbidities as prognostic variables for survival in myelofibrosis;Blood Advances;2023-03-02

3. Ruxolitinib-induced reactivation of cytomegalovirus and Epstein-Barr virus in graft-versus-host disease;Leukemia Research;2023-02

4. Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT;The Lancet Haematology;2023-01

5. JAK Inhibitors for the Management of Myeloproliferative Neoplasms;Pathogenesis and Treatment of Leukemia;2023